Abstract
Cardiovascular diseases (CVDs) have become a predominant cause of death worldwide. Although CVDs encompass a variety of pathological conditions that affect the heart and blood vasculature, they can be classified into two major groups according to their basic pathophysiologic mechanisms, namely atherosclerosis and aneurysm formation. Increasing evidence implicates micro-RNAs (miRNAs or miRs) as vital factors both in the initiation and progression processes of CVDs. Some miRs have a promoting role in CVD development, while others have a protective role. Today, miRs have been shown to be potential biomarkers for several types of CVDs, while strategies targeting miRs are under consideration as potential tools for exploitation in therapeutic approaches for CVD treatments. In this review, we present the available data on the involvement of miRs in CVDs, focusing on their role as regulators of the inflammatory process as an initiating and driving component of CVDs.
Keywords: Biomarkers, cardiovascular disease, inflammation, miRNAs.
Current Medicinal Chemistry
Title:MicroRNAs Determining Inflammation as Novel Biomarkers and Potential Therapeutic Targets
Volume: 22 Issue: 22
Author(s): Athanassios Kotsinas, Fragkiska Sigala, Spiros D. Garbis, Giorgos Galyfos, Konstantinos Filis, Konstantinos Vougas, Alexandros Papalampros, Elizabeth E. Johnson, Efstathios Chronopoulos, Alexandros G. Georgakilas and Vassilis G. Gorgoulis
Affiliation:
Keywords: Biomarkers, cardiovascular disease, inflammation, miRNAs.
Abstract: Cardiovascular diseases (CVDs) have become a predominant cause of death worldwide. Although CVDs encompass a variety of pathological conditions that affect the heart and blood vasculature, they can be classified into two major groups according to their basic pathophysiologic mechanisms, namely atherosclerosis and aneurysm formation. Increasing evidence implicates micro-RNAs (miRNAs or miRs) as vital factors both in the initiation and progression processes of CVDs. Some miRs have a promoting role in CVD development, while others have a protective role. Today, miRs have been shown to be potential biomarkers for several types of CVDs, while strategies targeting miRs are under consideration as potential tools for exploitation in therapeutic approaches for CVD treatments. In this review, we present the available data on the involvement of miRs in CVDs, focusing on their role as regulators of the inflammatory process as an initiating and driving component of CVDs.
Export Options
About this article
Cite this article as:
Kotsinas Athanassios, Sigala Fragkiska, Garbis D. Spiros, Galyfos Giorgos, Filis Konstantinos, Vougas Konstantinos, Papalampros Alexandros, Johnson E. Elizabeth, Chronopoulos Efstathios, Georgakilas G. Alexandros and Gorgoulis G. Vassilis, MicroRNAs Determining Inflammation as Novel Biomarkers and Potential Therapeutic Targets, Current Medicinal Chemistry 2015; 22 (22) . https://dx.doi.org/10.2174/0929867322666150716113304
DOI https://dx.doi.org/10.2174/0929867322666150716113304 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Preface
Current Medical Imaging Diverse Functions and Mechanisms of Pericytes in Ischemic Stroke
Current Neuropharmacology Editorial (Thematic Issue: Combination Therapy of Vascular Diseases and Fangjiomics: When West Meets East in the Era of Phenomics)
Current Vascular Pharmacology A Case of Pulmonary Tuberculosis Mimicking as Diffuse Alveolar Hemorrhage: A Case Report
New Emirates Medical Journal MCP-1/CCL2 as a Therapeutic Target in Myocardial Infarction and Ischemic Cardiomyopathy
Inflammation & Allergy - Drug Targets (Discontinued) Haptoglobin Genotype Affects Inflammation after Aneurysmal Subarachnoid Hemorrhage
Current Neurovascular Research COVID-19 and Autoimmune Diseases: A Systematic Review of Reported Cases
Current Rheumatology Reviews Relationships Between Alcohol Consumption, Smoking Status and Food Habits in Greek Adolescents. Vascular Implications for the Future
Current Vascular Pharmacology Bioactive Compound and Nanotechnology: A Novel Delivery Perspective for Diabetic Retinopathy
Current Bioactive Compounds Glaucoma Disease: A Survey
Current Medical Imaging Editorial (Thematic Issue: Therapeutic Potential of microRNAs in Vascular Disease)
Current Vascular Pharmacology CYP4 Enzymes As Potential Drug Targets: Focus on Enzyme Multiplicity, Inducers and Inhibitors, and Therapeutic Modulation of 20- Hydroxyeicosatetraenoic Acid (20-HETE) Synthase and Fatty Acid ω- Hydroxylase Activities
Current Topics in Medicinal Chemistry A Blood Vessel Deformation Model Based Virtual-reality Simulator for the Robotic Catheter Operating System
Neuroscience and Biomedical Engineering (Discontinued) Prevention of Endothelial Cell Injury by Activated Protein C: The Molecular Mechanism(s) and Therapeutic Implications
Current Vascular Pharmacology Template-Mediated Biomineralization for Bone Tissue Engineering
Current Stem Cell Research & Therapy Effect of Doxycycline on Atherosclerosis: From Bench to Bedside
Recent Patents on Cardiovascular Drug Discovery Intracranial Aneurysms in Sickle Cell Disease
Current Neurovascular Research Abdominal Aortic Aneurysm: What About Screening?
Current Pharmaceutical Design Matrix Metalloproteinase Inhibition in Atherosclerosis and Stroke
Current Molecular Medicine MEFV Mutation Carriers and Diseases Other than Familial Mediterranean Fever: Proved and Non-Proved Associations; Putative Biological Advantage
Current Drug Targets - Inflammation & Allergy